

Dispatch of Supplementary Scheme Booklet

Brisbane, Australia, 8 August 2022 – ResApp Health Limited (ASX:RAP) (**ResApp**) refers to its previous announcements made on 5 August 2022 in relation to the proposed acquisition of ResApp by Pfizer Australia Holdings Pty Limited (a wholly-owned subsidiary of Pfizer Inc., a global biopharmaceutical company) (**Pfizer**) by way of a scheme of arrangement (the **Scheme**).

Dispatch of Scheme Booklet

ResApp is pleased to announce that the supplementary explanatory statement (**Supplementary Scheme Booklet**) together with a personalised proxy form (**New Proxy Form**) has been dispatched to ResApp shareholders today. As noted in ResApp's ASX announcement on 3 August 2022, ResApp and Pfizer have entered into a further amended and restated scheme implementation deed (**Revised SID**) to increase the scheme consideration to A\$0.208 per share in cash (**Revised Scheme Consideration**) which matches the Independent Expert's preferred price. The Supplementary Scheme Booklet contains information about the Scheme, including the Revised Scheme Consideration.

A copy of the Supplementary Scheme Booklet is available electronically for viewing and downloading at:

ResApp's website: www.resapphealth.com.au
Scheme website: www.resappscheme.com
ASX website: <https://www2.asx.com.au/markets/company/rap/>

ResApp shareholders who have elected to receive electronic communications will receive an email containing instructions about how to view or download a copy of the Supplementary Scheme Booklet, as well as instructions on how to lodge their proxies for the Scheme Meeting online.

ResApp shareholders who have elected to receive communications via post will receive a printed copy of the Supplementary Scheme Booklet together with a New Proxy Form.

All other ResApp shareholders will receive a letter, together with a New Proxy Form, with instructions about how to view or download a copy of the Supplementary Scheme Booklet.

ResApp shareholders can also request a free hard copy of the Supplementary Scheme Booklet by calling the ResApp Shareholder Information Line on 1300 620 649 (within Australia) or +61 3 9415 4326 (outside Australia), Monday to Friday between 8:30am and 5:00pm (AEST).

ResApp shareholders should carefully read and consider both the Scheme Booklet released on 18 July 2022 and the Supplementary Scheme Booklet, including the materials annexed to both, before deciding how to vote at the Scheme Meeting. If after reading the Scheme Booklet or Supplementary Scheme Booklet you have any questions about the Scheme or either documents

please visit the Scheme website at www.resappscheme.com or contact the ResApp Shareholder Information Line on 1300 620 649 (within Australia) or +61 3 9415 4326 (outside Australia), Monday to Friday between 8:30am and 5:00pm (AEST).

Independent Expert Conclusion

The Supplementary Scheme Booklet contains a supplementary letter from BDO Corporate Finance WA Pty Limited (**Independent Expert**), which states the Independent Expert continues to conclude that the Scheme is in the best interests of ResApp shareholders, in absence of a Superior Proposal¹.

The Independent Expert's conclusion should be read in context with the full Independent Expert's report and Scheme Booklet released on 18 July 2022.

Director's recommendation

The Directors of ResApp continue to unanimously recommend that ResApp shareholders vote in favour of the Scheme, in the absence of a Superior Proposal and subject to the Independent Expert continuing to conclude that the Scheme is in the best interest of ResApp shareholders. Subject to those same qualifications, each Director intends to vote in favour of the Scheme with respect to the ResApp shares held or controlled by them.

Scheme Meeting

The Scheme Meeting is scheduled to take place at 2:00pm (AEST) on Friday, 19 August 2022 and will be held at the Four Seasons Hotel Sydney, 199 George Street, Sydney and virtually via an online platform. To attend the Scheme Meeting virtually, please pre-register in advance for the virtual meeting here:

https://us02web.zoom.us/webinar/register/WN_pvBR0ih1TKCkkQjgNNGNg

Due to the ongoing COVID-19 pandemic, in the interests of the health and safety of ResApp shareholders and staff, and uncertainty and disruption associated with Government restrictions on travel and large gatherings, to the extent practicable the Scheme Meeting will be held as a hybrid meeting which can be attended virtually or in person. ResApp encourages ResApp shareholders and their proxies, attorneys and corporate representatives to participate in the Scheme Meeting virtually.

Details of how to access the online platform, how to vote, appoint a proxy and how to participate in the Scheme Meeting are contained on the Scheme website at www.resappscheme.com. All

¹ As defined in the Revised SID announced to ASX on 3 August 2022.

proxy appointments must be received by Automic by no later 2:00pm (AEST) on Wednesday, 17 August 2022 to be effective.

Amending Resolution and previously submitted proxies

Previously validly submitted proxies in respect of the resolution contained in the Notice of Scheme Meeting annexed to the Scheme Booklet released on 18 July 2022 (**Scheme Resolution**) are valid unless revoked (**Existing Proxy**).

If you wish to amend or cancel your Existing Proxy, you must register a new proxy by either:

- lodging a replacement proxy online at <https://investor.automic.com.au/#/loginsah> and following the instructions provided; or
- completing and returning to Automic the New Proxy Form which accompanies the Supplementary Scheme Booklet.

If you do not have an Existing Proxy and you wish to vote by proxy, you must either lodge a proxy online using the address provided above or complete and return to Automic the New Proxy Form which accompanies the Supplementary Scheme Booklet.

At the Scheme Meeting, ResApp shareholders will be asked to consider a motion to amend the proposed Scheme Resolution which has previously been notified to shareholders with the Scheme Booklet, so as to take into account the Revised Scheme Consideration described in the Supplementary Scheme Booklet (**Amending Resolution**). The Amending Resolution will require an ordinary resolution of shareholders present and voting in person or by proxy, and voting will be by a poll. Assuming the Amending Resolution is approved, shareholders will then be invited to vote by poll for approval of the amended Scheme by adoption of the amended Scheme Resolution. The text of the amended Scheme is included in the Supplementary Scheme Booklet.

If you have an Existing Proxy and have not revoked your proxy instruction and you have instructed your proxy to vote in favour of the Scheme Resolution, the proxy will be considered to have authority to vote in favour of the Amending Resolution and the amended Scheme Resolution. If the Chair of the Scheme Meeting is appointed as your proxy (or is appointed by default), the Chair intends to vote all valid undirected proxies which he receives for (or in favour of) the Amending Resolution and the amended Scheme Resolution.

If you have an Existing Proxy and have not revoked your proxy instruction and you have instructed your proxy to vote against the Scheme Resolution, the proxy will be considered to have authority to vote against the Amending Resolution and the amended Scheme Resolution.

All proxy appointments, amendments and cancellations must be received no later than 2:00pm (AEST) on Wednesday, 17 August 2022 to be effective.

Second Court Hearing

If ResApp shareholders approve the Scheme at the Scheme Meeting and all relevant conditions of the Scheme are satisfied or waived, ResApp will apply to the Court for orders approving the Scheme.

Indicative Timeline

The key events and expected timing in relation to the approval and implementation of the Scheme are set out in the table below.

Latest time and date for lodgement of completed Proxy Form for the Scheme Meeting	2:00pm (AEST) on 17 August 2022
Time and date for determining eligibility of ResApp Shareholders to vote at the Scheme Meeting	7:00pm (AEST) on 17 August 2022
Time and date of the Scheme Meeting	2:00pm (AEST) on 19 August 2022
Second Court Date	9:15am (AEST) on 25 August 2022
Effective Date of the Scheme	26 August 2022
Last date of trading of ResApp Shares on ASX	26 August 2022
Implementation Date for the Scheme and payment	6 September 2022

Note: All stated dates and times are indicative only and subject to necessary approvals from the Court and each other condition precedent to the Scheme being satisfied or waived. ResApp has the right to vary the timetable detailed above subject to the approval of such variation by Pfizer, the Court and ASIC where required. Any changes to the above timetable will be announced to ASX and will be available under ResApp's profile on ASX at www.asx.com.au.

ResApp will update ResApp shareholders as to any material developments in relation to the Scheme as the timetable progresses.

Further information

If you require further information or have questions in relation to the Scheme, please visit the Scheme website at www.resappscheme.com or contact the ResApp Shareholder Information Line on 1300 620 649 (within Australia) or +61 3 9415 4326 (outside Australia), Monday to Friday between 8:30am and 5:00pm (AEST).

###



About ResApp Health Limited

ResApp Health Limited (ASX: RAP) is a leading digital health company developing smartphone applications for the diagnosis and management of respiratory disease. ResApp's machine learning algorithms use sound to diagnose and measure the severity of respiratory conditions without the need for additional accessories or hardware. ResApp's regulatory-approved and clinically validated products include ResAppDx, a smartphone-based acute respiratory disease diagnostic test; SleepCheckRx, a prescription-only smartphone application that screens adults for moderate to severe sleep apnoea; and SleepCheck, a smartphone application which allows consumers to self-assess their risk of sleep apnoea. For more information, please visit www.resapphealth.com.au.

Contacts

Dr Tony Keating
CEO and Managing Director
+61 430 180 659
tony@resapphealth.com.au

Mr Brian Leedman
Executive Director, Corporate Affairs
+61 412 281 780
brian@resapphealth.com.au

This ASX announcement was approved and authorised for release by the board of directors of ResApp Health.